Stage III NSCLC RWE in Chinese Patients | NCT04023812 | Trialant

Stage III NSCLC RWE in Chinese Patients | NCT04023812 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Cohort 1		Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC
Cohort 2		Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To observe treatment patterns of unresectable, stage III NSCLC	Treatment received before disease progress including chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis therapy and radiotherapy	Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months

Secondary Outcomes

Measure	Description	Time Frame
To observe the clinical outcome of unresectable, stage III NSCLC	Overall survival measured from the date of treatment initiation in the study to the date of death due to any cause; Progression-free Survival (PFS) measured from the date of treatment initiation in the study, until physician-reported progression or death due to any cause, whichever occurs first.	Date of enrollment in the study until end of follow-up or death if this occurs before, assessed approximately up to 36 months

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
42070217	Derived	Xing L, Yu J, Meng X, Zhao R, Yang W, Guo Y, Li J, Fan M, Xiao C, Ren Y, Dong L, Lv D, Zhao L, Lin Y, Zhang X, Chen L, Wang Y, Zhang Y, Zang A, Cheng G, Liu A, Liang N, Lou B, Wang J, Fu X, Shi A, Xu N, Liu J, Xiang ZL. Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study. Target Oncol. 2026 May;21(3):385-398. doi: 10.1007/s11523-026-01217-0. Epub 2026 May 3.

Condition Browse Module